Exatecan

Exatecan
Names
	IUPAC name (1S,9S)-1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione
Identifiers
CAS Number	171335-80-1 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL1614650 ;
ChemSpider	133194 ;
PubChem CID	151115;
UNII	OC71PP0F89 ;
CompTox Dashboard (EPA)	DTXSID60169061 ;
	InChI InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1 Key: ZVYVPGLRVWUPMP-FYSMJZIKSA-N ; InChI=1/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1 Key: ZVYVPGLRVWUPMP-FYSMJZIKBW;
	SMILES CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O; Fc2c(c6c1c(c5c(nc1c2)C=3N(C(=O)\C4=C(/C=3)[C@](O)(C(=O)OC4)CC)C5)[C@@H](N)CC6)C;
Properties
Chemical formula	C24H22FN3O4
Molar mass	435.455 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Exatecan is a drug which is a structural analog of camptothecin with antineoplastic activity.[1]

A derivative is used in Trastuzumab deruxtecan.

Synthesis

Exatecan synthesis[2]

gollark: ```Python 3.7.0 (default, Jul 15 2018, 10:44:58) [GCC 8.1.1 20180531] on linuxType "help", "copyright", "credits" or "license" for more information.>>> [a^a for a in range(10)][0, 0, 0, 0, 0, 0, 0, 0, 0, 0]>>> [a**a for a in range(10)][1, 1, 4, 27, 256, 3125, 46656, 823543, 16777216, 387420489]>>> ```

gollark: Use `**` for exponent.

gollark: I think it's because python `^` does XOR.

gollark: Your bot has now been added to heavserver, inevitably.

gollark: That is the right word, but no.

References

Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz, H; Tchekmedyian, NS; Feit, K; Ackerman, J; De Jager, RL; Eckhardt, SG; O'Reilly, EM (20 September 2006). "Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer". Journal of Clinical Oncology. 24 (27): 4441–7. doi:10.1200/JCO.2006.07.0201. PMID 16983112.
H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, U.S. Patent 5,834,476 (1998).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz, H; Tchekmedyian, NS; Feit, K; Ackerman, J; De Jager, RL; Eckhardt, SG; O'Reilly, EM (20 September 2006). "Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer". Journal of Clinical Oncology. 24 (27): 4441–7. doi:10.1200/JCO.2006.07.0201. PMID 16983112.

[2] H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, U.S. Patent 5,834,476 (1998).